Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Peretz

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2019
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)T Bachelot, E Ciruelos, A Schneeweiss, et al.
Blood|December 1, 1996
Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotypeD Ben-Yehuda, S Krichevsky, O Caspi, et al.
Clinical Genetics|November 29, 2014
Genetic features of Lynch syndrome in the Israeli populationY Goldberg, I Barnes-Kedar, I Lerer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2004
Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2O Merimsky, E Gez, R Weitzen, et al.
American Journal of Human Genetics|October 3, 1998
Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genesE Friedman, R Bar-Sade Bruchim, A Kruglikova, et al.
Human Heredity|August 22, 2001
Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer familiesA P Manning, D Abelovich, P Ghadirian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2021
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognosticationD Miles, E Ciruelos, A Schneeweiss, et al.
Breast Cancer Research and Treatment|March 12, 2022
Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian JewsS Lieberman, R Chen-Shtoyerman, Z Levi, et al.
Journal of Skin Cancer|February 1, 2013
Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanomaM Klein, M Lotem, T Peretz, et al.
ESMO Open|November 14, 2021
Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancerM Condorelli, M Bruzzone, M Ceppi, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2019
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)T Bachelot, E Ciruelos, A Schneeweiss, et al.
Blood|December 1, 1996
Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotypeD Ben-Yehuda, S Krichevsky, O Caspi, et al.
Clinical Genetics|November 29, 2014
Genetic features of Lynch syndrome in the Israeli populationY Goldberg, I Barnes-Kedar, I Lerer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2004
Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2O Merimsky, E Gez, R Weitzen, et al.
American Journal of Human Genetics|October 3, 1998
Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genesE Friedman, R Bar-Sade Bruchim, A Kruglikova, et al.
Human Heredity|August 22, 2001
Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer familiesA P Manning, D Abelovich, P Ghadirian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2021
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognosticationD Miles, E Ciruelos, A Schneeweiss, et al.
Breast Cancer Research and Treatment|March 12, 2022
Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian JewsS Lieberman, R Chen-Shtoyerman, Z Levi, et al.
Journal of Skin Cancer|February 1, 2013
Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanomaM Klein, M Lotem, T Peretz, et al.
ESMO Open|November 14, 2021
Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancerM Condorelli, M Bruzzone, M Ceppi, et al.
Pageof 11